- Clinical Trials
A new study published in Cancer Gene Therapy by independent researchers outlines REQORSA as a promising therapeutic candidate for combinational therapy in cancer
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is a leader in gene therapy with a systemic gene therapy in development for non-small cell lung cancer (NSCLC).
Dr. Mark Berger is a senior executive with 25 years of biotech and pharmaceutical company experience in the development of oncology therapeutics.
Genprex’s lead drug candidate, REQORSA™ Immunogene Therapy that uses our proprietary, non-viral ONCOPREX® Nanoparticle Delivery System was highlighted in a Key Opinion Leader event hosted by Alliance Global Partners (AGP) for their institutional customers.
Mr. Redman provides his reaction to a recent article in ONCOLOGY® and discusses how Genprex is harnessing breakthroughs in lung cancer treatment.
Genprex is supporting The Society for Immunotherapy of Cancer (SITC) and the Cancer Research Institute’s Annual Cancer Immunotherapy Month in June.
At Genprex, the health and well-being of the communities we serve, including those with cancer and diabetes, is our top priority.
March 30 marks National Doctors’ Day, an annual holiday when we can all acknowledge and show appreciation for our physicians who help save lives everywhere.
Genprex is harnessing the power of a combinational treatment approach to overcome treatment limitations and offer patients new treatment options.
Genprex is once again leading the way in gene therapy and raising the standard in cancer treatment based upon its unique, proprietary technology platform that includes its non-viral vector nanoparticle delivery system.